Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation

被引:69
作者
Weber, J
Chakraborty, B
Weberova, J
Miller, MD
Quiñones-Mateu, ME
机构
[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Sect Virol NN10, Cleveland, OH 44195 USA
[2] Case Western Reserve Univ, AIDS Res Ctr, Cleveland, OH 44106 USA
[3] Gilead Sci Inc, Foster City, CA USA
关键词
D O I
10.1128/JCM.43.3.1395-1400.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resistance mutation K65R confers intermediate levels of resistance to several RT inhibitors, including a three- to fourfold reduction of tenofovir susceptibility. Here, we have used for the first time primary HIV-1 isolates from individuals who developed the K65R mutation while enrolled in a clinical trial of tenofovir to analyze the impact of this mutation on HIV-1 replicative fitness. A marked impairment in replicative fitness was observed in association with the selection of viruses carrying the K65R mutation in all patients. The mean replicative fitness among these viruses was 20% relative to the corresponding baseline wild-type virus, ranging from 10 to 32% depending on the accompanying RT mutations. These results support a reduction in in vivo replication for K65R mutant viruses.
引用
收藏
页码:1395 / 1400
页数:6
相关论文
共 31 条
[1]  
BLOOR S, 2000, ANTIVIR THER S, V5, P169
[2]   pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D [J].
Cornelissen, M ;
vandenBurg, R ;
Zorgdrager, F ;
Lukashov, V ;
Goudsmit, J .
JOURNAL OF VIROLOGY, 1997, 71 (09) :6348-6358
[3]   Durable HIV treatment benefit despite low-level viremia - Reassessing definitions of success or failure [J].
Deeks, SG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02) :224-226
[4]   Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations [J].
Deval, J ;
White, KL ;
Miller, MD ;
Parkin, NT ;
Courcambeck, J ;
Halfon, P ;
Selmi, B ;
Boretto, J ;
Canard, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (01) :509-516
[5]  
Gallant JE, 2003, ANTIVIR THER, V8, P489
[6]   Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].
Gallant, JE ;
Staszewski, S ;
Pozniak, AL ;
DeJesus, E ;
Suleiman, JMAH ;
Miller, MD ;
Coakley, DF ;
Lu, B ;
Toole, JJ ;
Cheng, AK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201
[7]   A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation [J].
García-Lerma, JG ;
MacInnes, H ;
Bennett, D ;
Reid, P ;
Nidtha, S ;
Weinstock, H ;
Kaplan, JE ;
Heneine, W .
JOURNAL OF VIROLOGY, 2003, 77 (10) :5685-5693
[8]   IDENTIFICATION OF A MUTATION AT CODON-65 IN THE IKKK MOTIF OF REVERSE-TRANSCRIPTASE THAT ENCODES HUMAN-IMMUNODEFICIENCY-VIRUS RESISTANCE TO 2',3'-DIDEOXYCYTIDINE AND 2',3'-DIDEOXY-3'-THIACYTIDINE [J].
GU, ZX ;
GAO, Q ;
FANG, HS ;
SALOMON, H ;
PARNIAK, MA ;
GOLDBERG, E ;
CAMERON, J ;
WAINBERG, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (02) :275-281
[9]   Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: Genotypic, phenotypic, and rebound analyses [J].
Margot, NA ;
Isaacson, E ;
McGowan, I ;
Cheng, A ;
Miller, MD .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 33 (01) :15-21
[10]   Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF [J].
Margot, NA ;
Isaacson, E ;
McGowan, I ;
Cheng, AK ;
Schooley, RT ;
Miller, MD .
AIDS, 2002, 16 (09) :1227-1235